The group’s principle activity is to develop traditional chinese medicine into FDA approved prescription drugs for the treatment of cancer. The group’s preclinical products include PHY906, PHY626, PHY808 and PHY777. The group's quality control technology platform include PhytomicsQC(TM), Chemical Fingerprinting, Genomic Bioresponse Profiling, Phytomics Similarity Index(TM) and PhytoViewer(TM). The group operates from United States.
